THERAPEUTIC MODALITIES Archives - Page 3 of 22

PBMC Humanized Tumor Models for Evaluating T-cell Engagers

T-cell engagers (TCEs) are a class of bispecific antibody-based immunotherapies designed to bring T cells into close proximity with cancer...

Innovative Technologies in Early Drug Discovery

In this webinar, WuXi AppTec scientists discuss the latest innovative technologies and products in early-stage drug discovery. Viewers will gain...

Application of On-bead DEL Technology in Target Protein Degradation Phenotypic Screen

DNA-encoded library (DEL) technology has been recognized as a major screening method, offering unique advantages through its ability to provide...

Strategies for Advancing Molecular Glue Drug Discovery

In this webinar, WuXi Biology scientists showcase our end-to-end molecular glue discovery platform. Molecular glues act as “molecular adhesives”, facilitating...

mRNA Display: Unlocking Peptide Discovery

Introduction: In the realm of modern therapeutics, peptides have emerged as a powerful and versatile class of molecules, unlocking their...

Integrated Screening and Assay Capabilities Facilitate Peptide Drug Discovery

Peptide-based therapeutics have emerged as a significant class of drugs in the pharmaceutical landscape, offering numerous advantages, including high specificity,...

Strategies to Accelerate the Development of Antibody-Drug Conjugates

Antibody-drug conjugates (ADCs) hold great promise as cancer therapeutics, as they combine the precision of monoclonal antibodies with the potency...

Key Steps in Validating Targeted Protein Degraders

Choose excellence, choose WuXi Biology – your reliable partner in Targeted Protein Degradation (TPD) drug discovery. Since 2016, we have...

ADC Development: Preclinical Pharmacology Essentials

Antibody-drug conjugates (ADCs) are increasingly demonstrating their value in cancer treatment, especially in combination therapies and for targeting resistant cancer...

Knowledge Library